World news and discussion on TalkFuse.
Fashion retailers Marks and Spencer, John Lewis and Debenhams scale back plus size ranges as millions turn to fat jabs, researchers find
Marks and Spencer, John Lewis and Debenhams have scaled back the proportion of plus-size dresses in their ranges, according to new analysis by retail intelligence platform Edited, amid a surge in the use of weight loss injections such as Mounjaro. The findings, reported by The Daily Telegraph, suggest fashion retailers are recalibrating their offerings as GLP-1 drugs, once used mainly for type 2 diabetes, become increasingly mainstream, with some experts warning this risks "shutting out" larger customers from the high street.
Edited compared new dress listings from July and August this year with the same period in 2024 and found notable falls in the largest sizes. At M&S, dresses sized 18 and above fell from 34% to 27% of new listings, while sizes 22 to 24 dropped from 2.2% to just 0.4%. John Lewis's largest sizes fell from 22.3% to 19.2% of its range, and Debenhams' plus-size dresses fell from 23% to 17.4%, though Debenhams attributed this to its expansion to include more than 25,000 third-party brands rather than a cut to its own offering. By contrast, George at Asda held steady at 43-44%. Mintel research found 8% of British adults have used a GLP-1 injection or similar weight-loss medication, with predictions that up to one in eight Britons could be on such treatment by next year; both M&S and John Lewis said they remained committed to offering extended and inclusive sizing.
In short
- M&S, John Lewis and Debenhams cut plus-size dress ranges, study finds
- Change linked to rising use of weight loss jabs like Mounjaro
- Critics warn larger shoppers risk being "shut out" of high street fashion
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Retailers may need to adapt their ranges as customer demand changes, including if more shoppers lose weight while using GLP-1 medicines. They also make decisions about limited shelf space and stock based on sales and costs, so a smaller share of larger sizes could reflect commercial or operational changes rather than a judgement about those customers; Debenhams, for example, cited the expansion of third-party brands.
The case against
A shrinking share of larger sizes can leave plus-size shoppers with fewer choices and make them feel excluded from mainstream high-street fashion. The reported declines, particularly in the largest sizes, raise concerns that retailers may be responding to weight-loss trends at the expense of customers who still need those sizes, despite their stated commitment to inclusive ranges.
Explained simply
Clothing retailers choose which sizes to stock in each style, and those choices affect whether customers can find clothes that fit. “Plus-size” usually refers to sizes above the standard range, though the sizes included vary between brands.
Mounjaro and other GLP-1 medicines were developed to treat type 2 diabetes and are also used for weight loss. Their use has grown in Britain, prompting questions about whether changing demand is influencing what retailers sell.
The retailers named in the report have different ranges and business models, so changes in their listings may have different explanations. The issue matters to shoppers who need larger sizes, as well as to retailers deciding how broadly to cater for customers.
Americas Culture Fashion Research Science World
Discussion